TVTX
Travere Therapeutics Inc

1,379
Mkt Cap
$2.48B
Volume
2.58M
52W High
$42.13
52W Low
$12.91
PE Ratio
-44.51
TVTX Fundamentals
Price
$26.84
Prev Close
$27.72
Open
$27.70
50D MA
$29.58
Beta
1.51
Avg. Volume
1.5M
EPS (Annual)
-$0.5634
P/B
21.25
Rev/Employee
$987,380.28
$3,414.72
Loading...
Loading...
News
all
press releases
Elizabeth Reed Sells 10,000 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock
Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) insider Elizabeth Reed sold 10,000 shares of the company's stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $28.09, for a total value of $280,900.00. Following the completion of the...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Travere Therapeutics (NASDAQ:TVTX) Insider Sells $280,900.00 in Stock
Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) insider Elizabeth Reed sold 10,000 shares of the firm's stock in a transaction dated Monday, March 16th. The shares were sold at an average...
MarketBeat·3d ago
News Placeholder
Mirum Completes Enrollment in Late-Stage EXPAND Study of Livmarli
MIRM completes enrollment in phase III EXPAND study of Livmarli for treating additional rare cholestatic liver diseases. Top-line data due in Q4 2026.
Zacks·4d ago
News Placeholder
Cinctive Capital Management LP Makes New $2.26 Million Investment in Travere Therapeutics, Inc. $TVTX
Cinctive Capital Management LP purchased a new position in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) in the 3rd quarter, according to its most recent filing with the Securities...
MarketBeat·4d ago
News Placeholder
166,000 Shares in Travere Therapeutics, Inc. $TVTX Purchased by Apis Capital Advisors LLC
Apis Capital Advisors LLC purchased a new stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) in the third quarter, according to its most recent Form 13F filing with the...
MarketBeat·6d ago
News Placeholder
VRTX Stock Gains on Upbeat Interim Data From Kidney Disease Drug Study
Vertex stock jumps after interim phase III data show povetacicept cuts proteinuria 52% in IgA nephropathy study and boost hopes for accelerated FDA approval.
Zacks·11d ago
News Placeholder
Travere Therapeutics, Inc. $TVTX Shares Sold by GW&K Investment Management LLC
GW&K Investment Management LLC cut its holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 58.3% in the third quarter, according to its most recent disclosure with the Securities...
MarketBeat·14d ago
News Placeholder
Royce & Associates LP Reduces Stock Position in Travere Therapeutics, Inc. $TVTX
Royce & Associates LP decreased its position in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 67.7% during the third quarter, according to its most recent disclosure with the Securities...
MarketBeat·15d ago
News Placeholder
Legato Capital Management LLC Acquires Shares of 71,030 Travere Therapeutics, Inc. $TVTX
Legato Capital Management LLC purchased a new position in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) in the third quarter, according to its most recent filing with the Securities...
MarketBeat·18d ago
News Placeholder
Travere Therapeutics, Inc. (NASDAQ:TVTX) Given Average Rating of "Moderate Buy" by Analysts
Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) has been given an average recommendation of "Moderate Buy" by the fourteen ratings firms that are currently covering the firm, Marketbeat...
MarketBeat·21d ago
<
1
2
...
>

Latest TVTX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.